However, many challenges remain to be addressed in the practical utility of CAR-T therapy as follows [91]: (1) in the treatment using CD19 CAR-T cells, antigen escape frequently occurs, resulting in tumor immune tolerance [92]; (2) CAR-T recognizes healthy tissues and produces nontumor toxicity, which can be life-threatening in severe cases [93]; and (3) due to the complexity of TME of solid tumors, the efficacy of CAR-T is still not promising [94]. Here, CD19 is linked to neoplasm.